The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Therapeutic Pipeline Program, 2021Directed Evolution of Tailor-Made Molecular Chaperones
Study Rationale:
For cells to operate properly, the proteins they produce must fold properly and maintain the correct three-dimensional structure. This process relies on a special class of proteins... -
Therapeutic Pipeline Program, 2021Evaluation of a Drug that Removes Excess Iron from the Brain as a Treatment for Parkinson’s Disease
Study Rationale:
In Parkinson’s disease (PD), the death of cells in brain regions that control movement causes motor symptoms. Brain imaging studies show that iron builds up in these areas, damaging... -
Therapeutic Pipeline Program, 2021Development of Compounds that Destroy Alpha-Synuclein Aggregates for the Treatment of Parkinson’s Disease
Study Rationale:
Multiple lines of evidence indicate that alpha-synuclein forms aggregates similar to those adopted by infectious prion proteins, and that these toxic clusters are responsible for the... -
Priority Biology, 2021LRRK2 Regulation of Melanoma Progression
Study Rationale:
People with Parkinson's disease (PD) are more likely to develop melanoma, and people with melanoma are more likely to develop PD than the general population. Additionally, melanoma... -
Therapeutic Pipeline Program, 2021RNA Targeting Small Molecules as Therapeutics for Parkinson's
Study Rationale:
Abnormal clumping of the protein alpha-synuclein is a hallmark of Parkinson's disease (PD) and a likely cause of neurodegeneration and, ultimately, symptoms. One of the causes... -
Research Grant, 2021Codevelopment of Small-molecule Regulators of Miro1 for the Treatment of Parkinson’s Disease and a GLP Clinical Biomarker Assay
Study Rationale:
The mitochondrial protein Miro1 is elevated in more than 90% of all Parkinson’s disease (PD) patients of both genetic and sporadic forms. The high level of Miro1 is a pathogenic...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.